IDEX Corporation (IEX)

NYSEIndustrialsIndustrial - MachinerySnapshot 2026-10-15

$235.55-0.37%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge IDEX Corporation’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.2%

+10% or more+5%0%−5%−10% or less

9.68 → 9.70 EPS · FY ending Dec 31, 2027 · 9 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 9 to 9; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Consistent quarterly EPS beats	A supporting condition in IDEX Corporation's published investment case. The stated target is EPS beats in at least 3 of 4 quarters.	Intact	EPS misses in more than 1 quarter out of 4	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Full-year EPS guidance raised to $8.35-$8.55	It raised full-year EPS guidance to $8.35-$8.55.	Intact	EPS guidance falls below $8.35 for FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 6 of last 6 quarters. Adjusted diluted EPS guidance increased from $8.15-$8.35 in early 2026 to $8.70-$8.85 by 2026-Q2, representing about 10% growth year-over-year at midpoint. Actual adjusted EPS grew from $7.95 in 2025 to $8.70-$8.85 guidance in 2026, indicating delivery on EPS growth targets. Delivery assessment Oct 15, 2026
Organic sales growth of 3% to 4% annually	A primary condition in IDEX Corporation's published investment case. The stated target is 3% to 4% YoY.	Intact	Organic sales growth falls below 3% YoY in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 6 of last 6 quarters. Organic sales growth guidance increased from 1%-3% in 2025 to 5%-6% for full year 2026, with Q3 2026 organic sales projected to grow 5%-7%. Actual reported organic sales growth was 5% in 2026-Q2 and 5% in 2026-Q1, showing delivery on growth targets with an improving trajectory. Delivery assessment Oct 15, 2026
Active share repurchase program	A supporting condition in IDEX Corporation's published investment case. The stated target is At least $635 million authorized buybacks.	Intact	No buyback authorization or buyback program halted	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$9.70

$9.25 → $9.70 · observed estimates

FY2027 revenue$3.92B

$3.80B → $3.92B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$9.25	$3,801,853,140	15 / 14
2026-07-25	$9.25	$3,800,443,594	11 / 11
2026-07-26	$9.25	$3,800,443,594	11 / 11
2026-07-27	$9.25	$3,800,443,594	11 / 11
2026-07-28	$9.25	$3,800,443,594	11 / 11
2026-07-29	$9.25	$3,801,853,140	15 / 14
2026-07-30	$9.47	$3,871,885,815	10 / 10
2026-07-31	$9.47	$3,871,885,815	10 / 11
2026-08-01	$9.47	$3,871,885,815	10 / 11
2026-08-02	$9.46	$3,878,268,220	15 / 13
2026-08-03	$9.46	$3,878,268,220	15 / 13
2026-08-04	$9.47	$3,871,885,815	10 / 11
2026-08-05	$9.46	$3,878,268,220	15 / 13
2026-08-06	$9.46	$3,878,268,220	15 / 13
2026-08-07	$9.47	$3,871,885,815	10 / 11
2026-08-08	$9.47	$3,871,885,815	10 / 11
2026-08-09	$9.51	$3,885,175,910	15 / 13
2026-08-10	$9.47	$3,871,885,815	10 / 11
2026-08-12	$9.47	$3,871,885,815	10 / 11
2026-08-13	$9.53	$3,889,968,220	15 / 13
2026-08-14	$9.47	$3,871,885,815	10 / 11
2026-08-15	$9.47	$3,871,885,815	10 / 11
2026-08-16	$9.47	$3,871,885,815	10 / 11
2026-08-17	$9.47	$3,871,885,815	10 / 11
2026-08-18	$9.47	$3,871,885,815	10 / 11
2026-08-19	$9.47	$3,871,885,815	10 / 11
2026-08-20	$9.63	$3,903,916,733	10 / 11
2026-08-21	$9.63	$3,903,916,733	10 / 11
2026-08-22	$9.63	$3,903,916,733	10 / 11
2026-08-23	$9.63	$3,903,916,733	10 / 11
2026-08-24	$9.63	$3,903,916,733	10 / 11
2026-08-25	$9.63	$3,903,916,733	10 / 11
2026-08-26	$9.63	$3,903,920,067	10 / 11
2026-08-27	$9.63	$3,903,920,067	10 / 11
2026-08-28	$9.63	$3,903,920,067	10 / 11
2026-08-29	$9.63	$3,903,920,067	10 / 11
2026-08-30	$9.63	$3,903,920,067	10 / 11
2026-08-31	$9.63	$3,903,920,067	10 / 11
2026-09-01	$9.63	$3,903,920,067	10 / 11
2026-09-02	$9.63	$3,903,920,067	9 / 11
2026-09-03	$9.63	$3,903,920,067	9 / 11
2026-09-04	$9.63	$3,903,920,067	9 / 11
2026-09-05	$9.63	$3,903,920,067	9 / 11
2026-09-06	$9.63	$3,903,920,067	9 / 11
2026-09-07	$9.63	$3,903,920,067	9 / 11
2026-09-08	$9.63	$3,903,920,067	9 / 11
2026-09-09	$9.67	$3,913,940,263	9 / 11
2026-09-10	$9.68	$3,916,090,263	9 / 11
2026-09-11	$9.68	$3,916,090,263	9 / 11
2026-09-12	$9.68	$3,916,090,263	9 / 10
2026-09-13	$9.68	$3,916,090,263	9 / 10
2026-09-14	$9.68	$3,916,090,263	9 / 10
2026-09-15	$9.68	$3,916,090,263	9 / 10
2026-09-16	$9.68	$3,916,090,263	9 / 10
2026-09-17	$9.68	$3,916,090,263	9 / 10
2026-09-18	$9.68	$3,916,090,263	9 / 10
2026-09-19	$9.68	$3,916,090,263	9 / 10
2026-09-20	$9.68	$3,916,090,263	9 / 10
2026-09-21	$9.68	$3,916,090,263	9 / 10
2026-09-22	$9.68	$3,916,090,263	9 / 10
2026-09-23	$9.68	$3,916,090,263	9 / 10
2026-09-24	$9.68	$3,916,090,263	9 / 10
2026-09-25	$9.68	$3,916,090,263	9 / 10
2026-09-26	$9.68	$3,916,090,263	9 / 10
2026-09-27	$9.68	$3,916,090,263	9 / 10
2026-09-28	$9.68	$3,916,090,263	9 / 10
2026-09-29	$9.68	$3,916,090,263	9 / 10
2026-09-30	$9.68	$3,916,090,263	9 / 10
2026-10-01	$9.68	$3,916,090,263	9 / 10
2026-10-02	$9.68	$3,916,090,263	9 / 10
2026-10-03	$9.68	$3,916,090,263	9 / 10
2026-10-04	$9.68	$3,916,090,263	9 / 10
2026-10-05	$9.68	$3,916,090,263	9 / 10
2026-10-06	$9.68	$3,916,090,263	9 / 10
2026-10-07	$9.68	$3,916,090,263	9 / 10
2026-10-08	$9.68	$3,916,118,046	9 / 10
2026-10-09	$9.68	$3,916,118,046	9 / 10
2026-10-10	$9.68	$3,916,118,046	9 / 10
2026-10-11	$9.68	$3,916,776,420	9 / 10
2026-10-12	$9.68	$3,916,776,420	9 / 10
2026-10-13	$9.68	$3,916,776,420	9 / 10
2026-10-14	$9.68	$3,916,776,420	9 / 10
2026-10-15	$9.70	$3,919,443,087	9 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	9	7
2026-06-01	8	7
2026-07-01	8	7
2026-08-01	9	7
2026-09-01	10	6
2026-10-01	10	5

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 16–Oct 15 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Consistent quarterly EPS beatsDirect metric needs a verified mapping
Full-year EPS guidance raised to $8.35-$8.55Direct metric needs a verified mapping
Organic sales growth of 3% to 4% annuallyDirect metric needs a verified mapping
Active share repurchase programDirect metric needs a verified mapping

Next proof point

Oct 28, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.7%Typical daily move · historical

Downside history

-14.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

IDEX Corporation outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

IEX represents a durable compounder in the industrials sector. The current thesis is intact, supported by recent financial performance and management's focus on growth.

What's priced into IDEX Corporation

The market seems to have a neutral view on IEX's valuation, with a slight premium compared to peers. Expectations appear aligned with recent guidance and performance, indicating that the current price reflects a justified outlook.

What the fundamentals likely do

Fundamentals are likely to show continued organic sales growth, as management has consistently prioritized this area. The company has also raised its earnings guidance, suggesting a positive trajectory, though risks remain due to potential sector headwinds.

What IDEX Corporation hinges on

The thesis hinges on the performance of sector bellwethers like GEV, PH, and TT. If these companies continue to perform well, it could support IEX's growth. Conversely, any negative guidance from these peers could impact IEX's momentum.